191 related articles for article (PubMed ID: 17346679)
1. Spurious genetic associations.
Sullivan PF
Biol Psychiatry; 2007 May; 61(10):1121-6. PubMed ID: 17346679
[TBL] [Abstract][Full Text] [Related]
2. No associations exist between five functional polymorphisms in the catechol-O-methyltransferase gene and schizophrenia in a Japanese population.
Nunokawa A; Watanabe Y; Muratake T; Kaneko N; Koizumi M; Someya T
Neurosci Res; 2007 Jul; 58(3):291-6. PubMed ID: 17482701
[TBL] [Abstract][Full Text] [Related]
3. Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: influence on the severity of psychotic symptoms and on the response to neuroleptic treatment.
Molero P; Ortuño F; Zalacain M; Patiño-García A
Pharmacogenomics J; 2007 Dec; 7(6):418-26. PubMed ID: 17363961
[TBL] [Abstract][Full Text] [Related]
4. ARVCF single marker and haplotypic association with schizophrenia.
Mas S; Bernardo M; Parellada E; Garcia-Rizo C; Gassó P; Alvarez S; Lafuente A
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Aug; 33(6):1064-9. PubMed ID: 19508883
[TBL] [Abstract][Full Text] [Related]
5. Evidence of epistasis between the catechol-O-methyltransferase and aldehyde dehydrogenase 3B1 genes in paranoid schizophrenia.
Wang Y; Hu Y; Fang Y; Zhang K; Yang H; Ma J; Xu Q; Shen Y
Biol Psychiatry; 2009 Jun; 65(12):1048-54. PubMed ID: 19159868
[TBL] [Abstract][Full Text] [Related]
6. Genetic variation in COMT and PRODH is associated with brain anatomy in patients with schizophrenia.
Zinkstok J; Schmitz N; van Amelsvoort T; Moeton M; Baas F; Linszen D
Genes Brain Behav; 2008 Feb; 7(1):61-9. PubMed ID: 17504246
[TBL] [Abstract][Full Text] [Related]
7. Catechol-O-methyltransferase genotype is associated with plasma total homocysteine levels and may increase venous thrombosis risk.
Gellekink H; Muntjewerff JW; Vermeulen SH; Hermus AR; Blom HJ; den Heijer M
Thromb Haemost; 2007 Dec; 98(6):1226-31. PubMed ID: 18064318
[TBL] [Abstract][Full Text] [Related]
8. COMT Val 158 Met polymorphism is associated with cognitive flexibility in a signal discrimination task in schizophrenia.
Neuhaus AH; Opgen-Rhein C; Urbanek C; Hahn E; Ta TM; Seidelsohn M; Strathmann S; Kley F; Wieseke N; Sander T; Dettling M
Pharmacopsychiatry; 2009 Jul; 42(4):141-4. PubMed ID: 19585392
[TBL] [Abstract][Full Text] [Related]
9. Impact of schizophrenia candidate genes on schizotypy and cognitive endophenotypes at the population level.
Stefanis NC; Trikalinos TA; Avramopoulos D; Smyrnis N; Evdokimidis I; Ntzani EE; Ioannidis JP; Stefanis CN
Biol Psychiatry; 2007 Oct; 62(7):784-92. PubMed ID: 17336946
[TBL] [Abstract][Full Text] [Related]
10. Dysbindin and d-amino-acid-oxidase gene polymorphisms associated with positive and negative symptoms in schizophrenia.
Wirgenes KV; Djurovic S; Agartz I; Jonsson EG; Werge T; Melle I; Andreassen OA
Neuropsychobiology; 2009; 60(1):31-6. PubMed ID: 19729970
[TBL] [Abstract][Full Text] [Related]
11. Detailed analysis of the relative power of direct and indirect association studies and the implications for their interpretation.
Moskvina V; O'Donovan MC
Hum Hered; 2007; 64(1):63-73. PubMed ID: 17483598
[TBL] [Abstract][Full Text] [Related]
12. A principal components regression approach to multilocus genetic association studies.
Wang K; Abbott D
Genet Epidemiol; 2008 Feb; 32(2):108-18. PubMed ID: 17849491
[TBL] [Abstract][Full Text] [Related]
13. Effects of brain-derived neurotrophic factor-catecholamine-O-methyltransferase gene interaction on schizophrenic symptoms.
Han DH; Park DB; Choi TY; Joo SY; Lee MK; Park BR; Nishimura R; Chu CC; Renshaw PF
Neuroreport; 2008 Jul; 19(11):1155-8. PubMed ID: 18596619
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in catechol-O-methyltransferase and methylenetetrahydrofolate reductase in relation to the risk of schizophrenia.
Muntjewerff JW; Gellekink H; den Heijer M; Hoogendoorn ML; Kahn RS; Sinke RJ; Blom HJ
Eur Neuropsychopharmacol; 2008 Feb; 18(2):99-106. PubMed ID: 17716874
[TBL] [Abstract][Full Text] [Related]
15. COMT val158Met and executive control: a test of the benefit of specific deficits to translational research.
MacDonald AW; Carter CS; Flory JD; Ferrell RE; Manuck SB
J Abnorm Psychol; 2007 May; 116(2):306-12. PubMed ID: 17516763
[TBL] [Abstract][Full Text] [Related]
16. Relationship of catechol-O-methyltransferase to schizophrenia and its correlates: evidence for associations and complex interactions.
Lewandowski KE
Harv Rev Psychiatry; 2007; 15(5):233-44. PubMed ID: 17924258
[TBL] [Abstract][Full Text] [Related]
17. Association analysis of the glutamic acid decarboxylase 2 and the glutamine synthetase genes (GAD2, GLUL) with schizophrenia.
Arai S; Shibata H; Sakai M; Ninomiya H; Iwata N; Ozaki N; Fukumaki Y
Psychiatr Genet; 2009 Feb; 19(1):6-13. PubMed ID: 19125103
[TBL] [Abstract][Full Text] [Related]
18. A study of the PEMT gene in schizophrenia.
Liu Y; Zhang H; Ju G; Zhang X; Xu Q; Liu S; Yu Y; Shi J; Boyle S; Wang Z; Shen Y; Wei J
Neurosci Lett; 2007 Sep; 424(3):203-6. PubMed ID: 17720317
[TBL] [Abstract][Full Text] [Related]
19. Catechol-O-methyltransferase Val158Met polymorphism in relation to aggressive schizophrenia in a Korean population.
Kim YR; Kim JH; Kim SJ; Lee D; Min SK
Eur Neuropsychopharmacol; 2008 Nov; 18(11):820-5. PubMed ID: 18789857
[TBL] [Abstract][Full Text] [Related]
20. Genomewide association analysis followed by a replication study implicates a novel candidate gene for neuroticism.
van den Oord EJ; Kuo PH; Hartmann AM; Webb BT; Möller HJ; Hettema JM; Giegling I; Bukszár J; Rujescu D
Arch Gen Psychiatry; 2008 Sep; 65(9):1062-71. PubMed ID: 18762592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
